Physician profile
Ammar Bazerbashi
NPI 1205885704
$17,476.98
in general payments reported to CMS, 2019-2025
55 companies · $2,666 in 2025
The $2,666 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,977 · 2020: $2,674 · 2021: $2,047 · 2022: $2,520 · 2023: $3,122 · 2024: $2,472 · 2025: $2,666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,237 · Education: $22.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,237.24 |
| Education | $22.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,844.64 | 2019-2025 | Breztri, Saphnelo, Fasenra |
| Abbvie INC. | $2,047.08 | 2020-2025 | Vraylar, Rinvoq, Qulipta |
| Amgen INC. | $1,533.38 | 2019-2025 | Otezla, Otezla, Repatha |
| Novo Nordisk INC | $1,225.40 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,069.07 | 2019-2025 | Trelegy Ellipta |
| Corcept Therapeutics | $912.38 | 2021-2025 | Korlym |
| Janssen Biotech, INC. | $686.20 | 2019-2025 | Tremfya, Simponi Aria |
| Horizon Therapeutics Plc | $617.35 | 2019-2022 | |
| Intra-Sana Laboratories | $549.99 | 2024-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Takeda Pharmaceuticals U.S.A., INC. | $509.91 | 2019-2025 | Trintellix |
| Medexus Pharma, INC. | $469.01 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $441.23 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $440.46 | 2019-2025 | |
| Lilly USA, LLC | $396.41 | 2019-2025 | Mounjaro, Taltz, Zepbound |
| Merck Sharp & Dohme LLC | $262.56 | 2019-2023 | Belsomra, Steglatro |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ammar Bazerbashi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.